BioNTech Shuffles Board and Shutters Factories, All Eyes on Pumitamig's ASCO Debut
Published on 05/19/2026 at 08:51 | Redaktion boerse-global.de
BioNTech is entering a defining stretch. The company that became a household name through its Covid vaccine is now selling that legacy to fund a future built on cancer immunotherapy, and the next major checkpoint arrives later this month at the American Society of Clinical Oncology (ASCO) annual meeting. The stakes are high: positive data could validate a transformation that has so far failed to win over investors, while a miss would amplify pressure on a pipeline already running at a $557 million quarterly burn rate.
The focus falls squarely on Pumitamig, a bispecific immuno-modulatory candidate developed jointly with Bristol Myers Squibb. At ASCO, BioNTech will unveil results from the phase 2 portion of the ROSETTA-Lung-02 study, where Pumitamig combined with chemotherapy is going head-to-head against Merck’s blockbuster Keytruda (pembrolizumab) plus chemotherapy in previously untreated non-small cell lung cancer. The drug works by simultaneously inhibiting PD-L1 and neutralizing VEGF-A, and early data released in March already hinted at encouraging antitumor activity. A convincing showing on the ASCO stage would bolster BioNTech’s ambition to launch fifteen phase 3 trials by the end of 2026 and generate seven late-stage data events this year.
The financial backdrop to that scientific bet is both a strength and a source of strain. BioNTech’s first-quarter revenue came in at €118.1 million, well short of the €155.4 million consensus, as sales of its Covid shot continue to slide from €182.8 million a year earlier. Research and development expenses reached €557 million, underscoring the cost of pivoting into immuno-oncology and antibody-drug conjugates. The net loss for the quarter stood at €531.9 million. Yet a massive war chest offers ample cushion: as of March 31, the company held €16.8 billion in cash, cash equivalents and securities.
Should investors sell immediately? Or is it worth buying BioNTech?
That liquidity has enabled a measure of capital discipline that would have been unthinkable for a pure-play biotech burning through cash at this pace. At the virtual annual general meeting on May 15, shareholders authorized a stock buyback program worth up to $1 billion in American Depositary Shares, to run through May 6, 2027. The program had been cleared by the board on May 7, and chief financial officer Ramón Zapata framed it as a vote of confidence in BioNTech’s long-term growth outlook and capital allocation strategy. The move gives management flexibility to repurchase shares if the valuation becomes too attractive to ignore.
At the same time, BioNTech is aggressively pruning its cost base. The company plans to close manufacturing sites in Idar-Oberstein, Marburg and Tübingen, along with a facility in Singapore, affecting roughly 1,860 jobs. The restructuring is expected to deliver annual savings of up to €500 million by 2029, with the freed-up cash redirected toward the oncology pipeline. The message is clear: every euro that can be squeezed out of production will flow into the clinic.
Governance is also in flux. The supervisory board has been expanded from six to eight members, with the addition of Prof. Iris Löw-Friedrich and Susanne Schaffert. Helmut Jeggle was elected chairman, while Prof. Anja Morawietz and Prof. Rudolf Staudigl received renewed mandates. Beyond the boardroom, the founders themselves are stepping back: Ugur Sahin and Özlem Türeci announced in March that they plan to leave operational management by the end of 2026, a disclosure that triggered an 18% single-day share slide.
The stock has not recovered that lost ground. On Monday, BioNTech’s Frankfurt-listed shares closed at €76.25, a 15.2% decline over the past 30 days and roughly 25% below the year’s peak. Last Saturday’s close on the New York ADR market was $88.85, a modest 0.78% dip. The market remains skeptical, and the next big move will likely come from the ASCO podium at the end of May. Strong Pumitamig data would lend credibility to the entire oncology thesis; weak numbers would compound the challenges posed by pipeline costs, factory closures and a leadership transition. After months of shoring up its balance sheet and governance, BioNTech now needs its science to do the talking.
Ad
BioNTech Stock: New Analysis - 19 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
